
Multiple Myeloma Survival in 2026: How New CAR-T Therapy Is Pushing Rates to 62% — And What It Means for Your Case
Multiple myeloma is no longer the death sentence it once was — 2026 CAR-T breakthroughs have pushed 5-year survival to 62.4%, the biggest jump in decades. See survival rates by stage, which new FDA-approved therapies are changing outcomes, and the exact questions to bring to your next oncology appointment.









